Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase

Lemay A, André Lemay, A Lemay, Sandow J, J Sandow, Jürgen Sandow, Bureau M, Marc Bureau, M Bureau, Rodolphe Maheux, Maheux R, R Maheux, J Y Fontaine, Jean‐Yves Fontaine, Fontaine JY, Mérat P, Patrick Mérat, P Mérat
Fertility and Sterility · 1988 · vol. 49(3) , pp. 410–417 · doi:10.1016/s0015-0282(16)59764-7 · PMID:3125068 · W2401454792
article OA: closed CC0 ⤵ 15 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Subcutaneous infusion of a GnRH agonist initiated during the luteal phase effectively prevented follicular maturation, indicating a potential therapeutic strategy for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Six endometriosis patients were treated with continuous subcutaneous (SC) infusion of a luteinizing hormone-releasing hormone (LH-RH) agonist using an external osmotic minipump system. Serum estradiol (E2) was suppressed into the menopausal range within 1 to 2 weeks of treatment started between days 9 and 12 after ovulation. The down-regulation of the pituitary-ovarian axis was maintained for the 24 weeks of treatment. Endometriosis symptoms were relieved during the treatment. At control laparoscopy, implants had regressed markedly and some adhesions had softened, accounting for a significant 58.3% reduction in the mean total American Fertility Society score. Ovulation returned within 14 to 38 days. Four infertile women became pregnant within 2 to 5 months after cessation of treatment. Frequent side effects were hot flushes, and decreased vaginal secretion and libido. There were no significant changes in laboratory blood tests, including cholesterol. The urinary calcium/creatinine ratio increased during the treatment. Thus, starting the treatment in the luteal phase prevented initial follicular stimulation. A better efficacy of treatment would be achieved by the release of an LH-RH agonist at a constant daily rate.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Adult Buserelin Buserelin Endometriosis Endometriosis Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteal Phase Luteinizing Hormone Luteinizing Hormone Ovarian Follicle Ovarian Follicle Ovarian Follicle

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (15)

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:25.758913+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK